Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price target lifted by Piper Sandler from $78.00 to $104.00 in a research note published on Friday, Benzinga reports. Piper Sandler currently has a neutral rating on the biotechnology company’s stock. Several other research firms also recently commented on BPMC. Wedbush reiterated an outperform rating and issued […]
Blueprint Medicines (NASDAQ:BPMC) Upgraded to Market Perform at SVB Leerink themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Blueprint Medicines (NASDAQ:BPMC) PT Raised to $168 00 at The Goldman Sachs Group theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) CFO Michael Landsittel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $105.00, for a total value of $1,050,000.00. Following the transaction, the chief financial officer now owns 47,286 shares of […]
Blueprint Medicines (NASDAQ:BPMC) PT Raised to $125 00 at JMP Securities themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.